Abstract:P2X receptors are a family of extracellular ATP-gated trimeric cation channels that is widely distributed in human tissues. Quite some drug candidates targeting P2X receptors have entered into preclinical or main phases of clinical trials, but many of them failed due to low subtype-selectivity or species differences in pharmacological activities between human and experimental animals. Here, we identified the distinct inhibitory efficacies of NF110, a competitive inhibitor, between the rat (rP2X3) and human (hP2X3) P2X3 receptors. We demonstrated that this difference is determined by two amino acids located in the dorsal fin (DF) domain of P2X3 receptors. As revealed by mutagenesis, metadynamics, and covalent modification, NF110-mediated rP2X3 inhibition may be through a filling in the cavity formed by the DF, left flipper (LF) and lower body (LB) to partially, rather than fully, occupy the ATP-binding pocket. Moreover, substitution of residues located in the DF and/or LF domains of the rP2X2 receptor, a NF110-insensitive subtype, with the equivalent amino acids of rP2X3, bestowed the sensitivity of rP2X2 to NF110. The critical roles of the DF and LF domains in channel gating of P2X and low conservativity in residue sequences of those two domains raise the possibility that small molecules differentially interacting with the residues of the DF and LF domains of different P2X receptors may modulate channel’s activity in a subtype-selective manner. However, the possible species-specificity of P2X inhibitors/modulators makes it more complex when interpreting the preclinical data into clinical researches. Nevertheless, our data provide new insights into the subtype-selectivity of competitive inhibitors and their distinct potencies in the human and experimental animals, both of which are extremely important in the drug discovery of P2X receptors.

Structural insights into the orthosteric inhibition of P2X receptors by non-ATP analog antagonists

Structural insights into the orthosteric inhibition of P2X receptors by non-ATP-analog antagonists

Structural Insights into the Competitive Inhibition of the ATP-gated P2X Receptor Channel

P2X7 receptors exhibit at least three modes of allosteric antagonism

Structural Insights into the Allosteric Inhibition of P2X4 Receptors

Cryo-EM structures of the human P2X1 receptor reveal subtype-specific architecture and antagonism by supramolecular ligand-binding

Structural insights into the human P2X1 receptor and ligand interactions

P2X 7 receptors exhibit at least three modes of allosteric antagonism

Recent progress in the structural biology of P2X receptors

Insights into the Channel Gating of P2X Receptors from Structures, Dynamics and Small Molecules

Molecular Mechanism Underlying the Subtype-Selectivity of Competitive Inhibitor NF110 and Its Distinct Potencies in Human and Rat P2X3 Receptors

Structural Insights into the Nucleotide Base Specificity of P2X Receptors

Ionotropic purinergic receptor 7 (P2X7) channel structure and pharmacology provides insight regarding non-nucleotide agonism

Structural Insights into Divalent Cation Modulations of ATP-Gated P2X Receptor Channels.

A shared mechanism for TNP-ATP recognition by members of the P2X receptor family

Full-Length P2X7 Structures Reveal How Palmitoylation Prevents Channel Desensitization

Finely ordered intracellular domain harbors an allosteric site to modulate physiopathological function of P2X3 receptors

Molecular determinants for agonist recognition and discrimination in P2X2 receptors

High-affinity agonism at the P2X7 receptor is mediated by three residues outside the orthosteric pocket

Molecular Mechanisms of Human P2X3 Receptor Channel Activation and Modulation by Divalent Cation Bound ATP

Molecular Mechanism of ATP Binding and Ion Channel Activation in P2X Receptors